Also from this source

You just read:

Ibrutinib (IMBRUVICA®) HELIOS Interim Analysis Study Data Show Significant Reductions in Risk of Progression or Death in Patients with Previously-Treated Chronic Lymphocytic Leukemia

News provided by

Janssen Research & Development, LLC

May 30, 2015, 07:32 ET